Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. by Madec, Y et al.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Response to highly active antiretroviral therapy
among severely immuno-compromised HIV-infected
patients in Cambodia
Yoann Madec
a, Didier Laureillard
b,c, Loretxu Pinoges
d, Marcelo
Fernandez
b,c, Narom Prak
b, Chanchhaya Ngeth
b, Sumanak Moeung
b,
Sovannara Song
b, Suna Balkan
c, Laurent Ferradini
d,
Catherine Quillet
b,c and Arnaud Fontanet
a
Background: HAART efﬁcacy was evaluated in a real-life setting in Phnom Penh
(Me ´decins Sans Frontie `res programme) among severely immuno-compromised
patients.
Methods: Factors associated with mortality and immune reconstitution were identiﬁed
using Cox proportional hazards and logistic regression models, respectively.
Results: From July 2001 to April 2005, 1735 patients initiated HAART, with median
CD4 cell count of 20 (inter-quartile range, 6–78) cells/ml. Mortality at 2 years
increased as the CD4 cell count at HAART initiation decreased, (4.4, 4.5, 7.5 and
24.7% in patients with CD4 cell count >100, 51–100, 21–50 and  20cells/ml,
respectively; P<10
 4). Cotrimoxazole and ﬂuconazole prophylaxis were protective
against mortality as long as CD4 cell counts remained  200 and  100cells/ml,
respectively. The proportion of patients with successful immune reconstitution (CD4
cell gain >100cells/ml at 6 months) was 46.3%; it was lower in patients with
previous ART exposure [odds ratio (OR), 0.16; 95% conﬁdence interval (CI), 0.05–
0.45] and patients developing a new opportunistic infection/immune reconstitution
infection syndromes (OR, 0.71; 95% CI, 0.52–0.98). Similar efﬁcacy was
found between the stavudine–lamivudine–nevirapine ﬁxed dose combination
and the combination stavudine–lamivudine–efavirenz in terms of mortality and
successful immune reconstitution. No surrogate markers for CD4 cell change could
be identiﬁed among total lymphocyte count, haemoglobin, weight and body mass
index.
Conclusion: Although CD4 cell count-stratiﬁed mortality rates were similar to those
observed in industrialized countries for patients with CD4 cell count >50cells/ml,
patients with CD4 cell count  20cells/ml posed a real challenge to clinicians. Wide-
spread voluntary HIV testing and counselling should be encouraged to allow HAART
initiation before the development of severe immuno-suppression.
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Introduction
In industrialized countries, highly active antiretroviral
therapy (HAART) has signiﬁcantly improved the life
expectancy of HIV-infected patients [1,2]. However, the
vast majority of HIV-infected patients is located in
developing countries, causing the World Health Organ-
ization (WHO) propose guidelines for scaling-up anti-
retroviral therapy (ART) in resource-poor settings and
launcha‘3 5’plantoprovideARTto3millionpatientsby
2005 [3]. Together with this initiative, numerous
programmes have been started in recent years to offer
HAARTtoHIV-infectedpatientsindevelopingcountries.
Recent publications have shown good response to
treatment in most resource-poor settings [4–7], with an
estimated 1-year mortality of 6.4% in a pooled analysis of
18 programmes [5]. Such good response may not be seen
withallHIV-infectedpatientsinthedevelopingworld,and
particularlyamongthosewhodiscovertheirHIVinfection
as a result of hospitalization for an opportunistic infection.
In such circumstances, patients often have very advanced
immuno-suppression,withCD4þT-cell(CD4cell)count
less than 50cells/ml at treatment initiation. This article
presents the results of a cohort study among 1735 patients
with advanced immuno-suppression (median CD4 cell
count¼20cells/ml at HAART initiation) as part of a
hospital-based treatment programme in Cambodia.
Patients and methods
Patients
Since July 2001, HIV-infected patients attending the
Preah Bath Norodom Sihanouk Hospital in Phnom
Penh (Cambodia) have had access to free HAART
through the Me ´decins Sans Frontie `res (MSF) programme.
Following WHO recommendations, eligibility criteria
for HAART were WHO stage IV or a CD4 cell count
below 200cells/ml [3]. Several ﬁrst-line treatments were
available, the choice depending on drug availabilityas well
as national policy recommendations. Thus, the combi-
nation stavudine (d4T), lamivudine (3TC), efavirenz
(EFV) was predominantly administrated until 2004, and
the combination d4T, lamivudine (3TC) and nevirapine
(NVP), given as a ﬁxed-dose combination (FDC) was
largely used thereafter. Physicians were instructed to
prescribe cotrimoxazole (480mg/day) and ﬂuconazole
(200mg/day) prophylaxis to patientswith CD4 cell count
 200and 50cells/ml,respectively(in2003,thedecision
was made to extend ﬂuconazole indication to those with
CD4 cell count  100cells/ml). Following HAART
initiation, patients were seen monthly for 6 months, and
then every 2 months. All patients’ data were routinely
entered in Fuchia v1.5 (Epicentre – MSF), and included
the following information: (1) at enrolment: age, sex,
residence, height, weight, WHO clinical stage [8], ART
history, ﬁrst-line therapy and prophylactic therapy; (2) at
eachfollow-uporunscheduledvisit:weight,clinicalevents
since last visit, treatment changes, treatment side effects,
prophylactic therapy.
Laboratory analysis
At treatment initiation, and every 6 months thereafter,
whole blood samples were collected on anticoagulant for
totallymphocytecount,CD4cellcount,andhaemoglobin
determination. Measurements were performed at the
Institut Pasteur in Phnom Penh. CD4 cell counts were
obtained using FACSCalibur ﬂow cytometry technology
(BD Biosciences, Immunocytometry Systems, San Jose,
California, USA).
Statistical methods
The analysis included all adult patients ( 13 years of age)
whoinitiatedHAARTbetweenJuly2001andApril2005.
The effect of HAART was ﬁrst investigated in terms of
progression to death, by estimating Kaplan–Meier
estimates. In this analysis, patients lost to follow-up, i.e.
not seen for more than 3 months, were considered dead
(n¼37). A Cox model was used to identify prognostic
factors of death. Factors included in the model were
(a) baseline data such as age, sex, WHO clinical stage,
biological markers (CD4 cell count, total lymphocyte
count, haemoglobin), body mass index (BMI), year of
HAART initiation, drug regimen used and previous
exposuretoART;and(b)time-dependentvariablessuchas
cotrimoxazole and ﬂuconazole prophylaxis. The d4T–
3TC–NVP FDC and the combination d4T–3TC–EFV
were compared using an intention to treat approach, thus
ignoring treatment modiﬁcations as well as interruptions.
Total lymphocyte count and haemoglobin were categor-
izedaccordingtoquartiles,whereasforCD4cellcountthe
four following categories were deﬁned:  20, 21–50,
51–100and>100cells/ml.Threecategoriesweredeﬁned
for the BMI (<17, 17–18.5 and >18.5kg/m
2); the ﬁrst
cut-off corresponds to the ﬁrst quartile, while the second
cut-off correspond to the Food and Agriculture Organ-
izationthresholdfor malnutrition[9].ForCD4cellcounts
and other laboratory markers, a category for missing data
was introduced when results were not available. In most
cases,missingdatacorrespondedtopatientswithverypoor
healthstatuswhodidnotneedCD4cellcounttodecideon
HAARTindication.Furthermore,themortalityrateratios
associatedwiththeuseofcotrimoxazoleandofﬂuconazole
were compared across time-varying CD4 cell count
categories.
The CD4 distributions at HAART initiation (measured
within a maximum of 6 months preceding HAART
initiation), and at 6 ( 1) months and 12 ( 2) months
after HAART initiation were compared to study immune
reconstitution. The time to reach the critical threshold of
200CD4cells/ml, at which the risk of opportunistic
infections (OI) is reduced, was estimated for each of the
baseline CD4 cell count categories. Immune reconstitu-
tion was considered as successful if the CD4 cell count
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gain, 6 months after HAART initiation, was at least
100cells/ml [10,11]. Factors associated with a successful
immune reconstitution were identiﬁed using a logistic
regression model.
Due to the limited clinical investigations available on site,
it was often difﬁcult to distinguish new OIs from immune
reconstitution infection syndromes (IRIS) after HAART
initiation, thus the two conditions were not differentiated
for the analysis. Post-HAART incidence of OI/IRIS was
estimated, and factors associated with the occurrence of
OI/IRIS were studied using a Cox model.
Total lymphocyte count, haemoglobin, weight and BMI
gains were evaluated as potential surrogate markers for
CD4 cell gain 1 year after HAART initiation. For this
purpose,thestrengthofthecorrelationbetweenCD4cell
gain and each surrogate marker gain was assessed by
computing the Spearman correlation coefﬁcient. The
sensitivity and speciﬁcity of speciﬁc marker changes (e.g.,
lowest quartile of lymphocyte count gain) in predicting
CD4 cell count gain  60cells/ml (lowest decile) after 1
year were also estimated.
Statistical analyses were performed using Stata 8 software
(Stata Corporation, College Station, Texas, USA); all
signiﬁcance tests were two-sided and P-values <0.05
were considered signiﬁcant.
Results
Between July 2001 and April 2005, 1735 adults initiated
HAART, among which 792 (45.6%) had clinical AIDS
(Table 1). The median duration of follow-up under
HAART at the time of analysis was 13 months [inter-
quartile range (IQR), 5–21 months]. Median CD4 cell
count at HAART initiation was 20cells/ml (IQR, 6–78).
Men were at a more advanced stage of infection in
comparison with women, as shown by the larger
proportion with clinical AIDS (54.5 versus 33.3%;
P<0.001), and the lower median CD4 cell count
(11 versus 46cells/ml, P<0.001).
Of the 1735 patients, 968 (55.8%) initiated HAARTwith
the combination d4T–3TC–EFV, 711 (41.0%) with the
FDC d4T–3TC–NVP, and 56 (3.2%) with other three-
drug combinations. In 30 patients, HAART combination
was changed, introducing a new therapeutic class (switch
to second line), after a median delay of 11.4 months
(IQR, 3.7–17.8). In 766 other patients, HAART
combination was changed without introduction of a
new therapeutic class; changes were switch from EFV to
NVP (42.5%), d4T to zidovudine (40.7%) or NVP to
EFV (13.1%), other changes were rare. Switches from
EFV to NVP were related to changes in national policy
recommendations, other switches were mostly motivated
by intolerance. During the follow-up, 209 patients
discontinued HAART for a median time of 1.1 months
(IQR, 0.5–2.4 months).
Mortality after HAART initiation
Of the 1735 patients who initiated HAART, 186 patients
died and 37 were lost to follow-up during 1955 person-
years of follow-up. Out of these patients, 103 (46.1%)
died within 3 months after HAART initiation. Using
Kaplan–Meier estimates, the death rates [95%conﬁden-
ceinterval(CI)] at 24 months according to the four CD4
cell count categories were: 24.7% (21.4–28.4%), 7.5%
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Table 1. Individual characteristics at HAART initiation by gender.
Men Women
N¼1010 (58.2%) N¼725 (41.8%) P-value
Age (years)
Median (IQR) 35 (31–39) 32 (28–38) <0.001
WHO stage
I 13 (1.3%) 40 (5.5%) <0.001
II 37 (3.7%) 64 (8.8%)
III 409 (40.5%) 380 (52.4%)
IV 551 (54.5%) 241 (33.3%)
BMI
N (%) 857 (84.9%) 600 (82.8%)
Median (IQR) (kg/m
2) 18.5 (16.6–20.4) 18.7 (16.4–21.0) 0.87
CD4 cell count
N (%) 923 (91.4%) 693 (95.6%)
Median (IQR) (cells/ml) 11 (4–41) 46 (11–118) <0.001
Lymphocyte count
N (%) 876 (86.7%) 667 (92.0%)
Median (IQR) (cells/ml) 1320 (960–1790) 1370 (1000–1800) 0.79
Haemoglobin level
N (%) 705 (69.8%) 510 (70.3%)
Median (IQR) (g/dl) 11.9 (10.2–13.0) 10.6 (9.5–12.0) <0.001
BMI, body mass index; IQR, inter-quartile range; WHO, World Health Organization.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
(4.5–12.5%), 4.5% (2.2–8.9%) and 4.4% (2.1–9.0%),
respectively (P<0.001) (Fig. 1). P-values comparing the
categories 21–50 versus 51–100, 21–50 versus >100,
and 51–100 versus >100 were all non-signiﬁcant.
Table 2 shows the factors associated with the death rate
i nam u l t i v a r i a t eC o xm o d e l :a g ea b o v e4 5y e a r s ,l o w
CD4 cell count ( 50cells/ml), WHO clinical stage IV
(AIDS),BMI 17kg/m
2,andHAARTdiscontinuation
>1 month were all independently associated with a
higher risk of death, whereas cotrimoxazole and
ﬂuconazole prophylactic treatments were protective.
In Table 3, the protective effect of cotrimoxazole and
ﬂuconazole prophylaxis is described according to time-
dependent CD4 cell count categories. It can be seen that
the recommendation to provide cotrimoxazole pro-
phylaxis to patients with CD4 cell count  200cells/ml
was properly followed (only 37.9 person-years of
follow-up without cotrimoxazole), whereas that of
providing ﬂuconazole prophylaxis was less properly
followed (259.6 person-years without ﬂuconazole). Of
interest, the protective effect of cotrimoxazole was
limited to patients with CD4 cell count  200cells/ml,
and that of ﬂuconazole to patients with CD4 cell count
 100cells/ml.
Immune reconstitution after HAART
The median CD4 cell count at HAART initiation,
available in 1616 patients, was 20cells/ml (IQR, 6–78),
and was above 200cells/ml in only 16 patients. The CD4
cell count increased after HAART initiation (Fig. 2) to
reach median levels of 130cells/ml( I Q R ,8 7 –189) at 6
months and 189cells/ml (IQR, 135–250) at 12 months.
Times to reach CD4 cell counts above 200cells/ml were
median 17.7, 16.4, 11.1, and 6.5 months for initial CD4
cellcountsat 20,21–50,51–100and101–150cells/ml,
respectively.
The CD4 cell count gain, estimated in 1040 patients,
was in median þ94cells/ml( I Q R ,5 9 –131cells/ml);
within the four baseline CD4 cell count categories
( 20, 21–50, 51–100 and >100) the median gains were
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Fig. 1. Kaplan–Meier survival curve according to (a) age (in years); (b) WHO clinical stage; (c) baseline CD4 cell count (in cells/
ml); and (d) body mass index (BMI, in kg/m
2).Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 2. Factors associated with progression to death after HAART initiation.
N (%) Crude HR (95% CI) Adjusted HR (95% CI)
Sex
Men 1010 (58.2) 1
Women 725 (41.8) 0.60 (0.50–0.87)
Age at HAART initiation (years)
<30 477 (27.5) 1.03 (0.77–1.39) 0.88 (0.65–1.19)
30–45 1132 (65.2) 1 1
 45 126 (7.3) 1.55 (0.99–2.44) 1.83 (1.16–2.90)
WHO stage at HAART initiation
I–II 154 (8.9) 0.74 (0.36–1.56) 0.73 (0.33–1.63)
III 789 (45.5) 1 1
IV 792 (45.6) 2.66 (1.98–3.58) 1.86 (1.37–2.53)
CD4 cell count at HAART initiation (cells/ml)
 20 826 (47.6) 7.09 (3.49–14.42) 8.93 (4.17–19.14)
20–50 249 (14.3) 2.20 (0.93–5.20) 2.78 (1.14–6.81)
50–100 232 (13.4) 1.22 (0.46–3.24) 1.65 (0.61–4.43)
>100 309 (17.8) 1 1
Missing 119 (6.9) 10.03 (4.57–22.01) 10.58 (4.69–23.89)
Lymphocyte count at HAART initiation (cells/ml)
 970 390 (22.5) 4.22 (2.66–6.71)
970–1340 382 (22.0) 1.97 (1.19–3.26)
1340–1800 393 (22.7) 1.37 (0.81–2.33)
>1800 378 (21.7) 1
Missing 192 (11.1) 4.16 (2.50–6.94)
Haemoglobin level at HAART initiation (g/dl)
 10 384 (22.1) 2.04 (1.14–3.67)
10–11 242 (14.0) 1.74 (0.92–3.27)
11–13 405 (23.3) 1.31 (0.71–2.42)
>13 184 (10.6) 1
Missing 520 (30.0) 2.89 (1.64–5.10)
BMI at HAART initiation (kg/m
2)
 18.5 749 (43.2) 1 1
17–18.5 276 (15.9) 1.14 (0.71–1.82) 0.88 (0.54–1.41)
<17 432 (24.9) 3.80 (2.78–5.22) 2.47 (1.77–3.43)
Missing 278 (16.0) 1.37 (0.86–2.17) 1.11 (0.69–1.78)
Baseline HAART regimen
d4T–3TC–EFV 968 (55.8) 1
d4T–3TC–NVP 711 (41.0) 0.74 (0.54–1.01)
Other 56 (3.2) 1.06 (0.52–2.16)
HAART discontinuation >1 month
a
No – 11
Yes – 4.18 (2.88–6.06) 3.23 (2.19–4.77)
Switch to second line
a
No – 1
Yes – 2.61 (0.96–7.06)
Year of HAART initiation
2001–2002 202 (11.6) 1.45 (1.00–2.09) 1.22 (0.84–1.78)
2003 669 (38.6) 1 1
2004–2005 864 (49.8) 1.45 (1.07–1.98) 1.64 (1.19–2.27)
Previous exposure to ART
No 1652 (95.2) 1
Yes 83 (4.8) 1.27 (0.71–2.27)
Cotrimoxazole during HAART
a
No – 11
Yes – 0.16 (0.11–0.21) 0.15 (0.11–0.21)
Fluconazole during HAART
a
No – 11
Yes – 1.13 (0.84–1.52) 0.50 (0.35–0.72)
ART, antiretroviral therapy; BMI, body mass index; CI, conﬁdence interval; d4T, stavudine; EFV, efavirenz; HR, hazard ratio; NVP, nevirapine;
WHO, World Health Organization’ 3TC, lamivudine.
aTime-dependent covariate in the Cox model.Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
90cells/ml (IQR, 62–123), 107cells/ml( I Q R ,6 7–145),
99cells/ml( I Q R ,6 7 –140) and 74cells/ml (IQR,
34–133), respectively. At 12 months, the CD4 cell count
gain was in median þ149cells/ml (IQR, 99–207)
(estimated in 795 patients).
ACD4cellcountgainof atleast100cells/mlat6months
was considered as a successful immune reconstitution,
and was achieved in 481 (46.3%) patients. In the
multivariate logistic regression model, female gender
[odds ratio (OR), 1.67; 95% CI, 1.28–2.19], age lower
than 30 years (OR, 1.43; 95% CI, 1.07–1.90, when
compared with age 30–45 years as the reference
category), CD4 cell count between 21 and 50cells/ml
at HAART initiation (OR, 2.15; 95% CI, 1.38–3.37,
when compared with CD4 cell count >100cells/mla s
the reference category) were all positively associated
with a successful immune reconstitution, while
previous exposure to ART (OR, 0.16; 95% CI,
0.05–0.45) and occurrence of a new OI/IRIS in the
6 months after HAART initiation (OR, 0.71; 95% CI,
0.52–0.98) were negatively associated with a successful
immune reconstitution.
Six and 12 months after HAART initiation, the median
total lymphocyte gains were þ525cells/ml (IQR, 50–
1040) and þ790cells/ml (IQR, 260–1340), respectively;
the median haemoglobin gains were þ1.3g/dl (IQR,
0.4–2.6) and þ2.0g/dl (IQR, 0.8–3.1), respectively; the
median weight gains were þ4kg (IQR, 1–7) and þ4kg
(IQR, 1–8), respectively; and the median BMI gains
were þ1.4kg/m
2 (IQR, 0.4–2.8) and þ1.6kg/m
2
(IQR, 0.3–3.2), respectively. The Spearman correlation
coefﬁcients between CD4 cell count gain and total
lymphocyte gain at 6 and 12 months were 0.45 and
0.51 (P<0.001), respectively; although signiﬁcant,
correlations with haemoglobin, weight and BMI gains
were weaker (data not shown). When trying to identify
surrogate markers changes that could predict CD4 cell
count gains  60cells/ml at 12 months (lowest decile),
none came out with satisfactory sensitivity and speciﬁcity
(data not shown).
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Table 3. Effect of cotrimoxazole and ﬂuconazole prophylaxis on the mortality rate.
With cotrimoxazole Without cotrimoxazole
CD4 count (cells/ml) Deaths Person-years Mortality rate
a Deaths Person-years Mortality rate
a Mortality rate ratio (95% CI)
 100 100 702.4 14.2 34 18.0 183.8 0.08 (0.05–0.11)
101–200 19 582.5 3.2 4 19.4 20.6 0.16 (0.05–0.46)
>200 6 314.2 1.9 6 168.0 3.6 0.53 (0.17–1.65)
With ﬂuconazole Without ﬂuconazole
CD4 count (cells/ml) Deaths Person-years Mortality rate
a Deaths Person-years Mortality rate
a Mortality rate ratio
 50 81 419.2 19.3 34 26.0 130.8 0.15 (0.10–0.22)
51–100 10 198.5 5.0 9 76.7 11.7 0.43 (0.17–1.06)
101–200 2 84.8 2.4 21 517.1 4.1 0.58 (0.14–2.48)
>200 0 14.7 0.0 12 467.6 2.6 0.0 (0.0–15.8)
aPer 100 person-years.
(b)
(a)
−200
0
200
400
600
(1) (1) (2) (2) (3) (3) (4) (4)
0
200
400
600
800
Cells/µl
At HAART initiation
N = 1616
At 6 months
N = 1094
At 12 months
N = 835
At 6 months
N = 1040
At 12 months
N = 795
Cells/µl
Fig. 2. Immune reconstitution after HAART initiation. (a)
CD4 cell count distribution; (b) CD4 cell count gain from
HAART initiation, according to the CD4 level at HAART
initiation [(1)  20cells/ml; (2) 21–50cells/ml; (3) 51–
100cells/ml; (4) >100cells/ml].Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Occurrence of opportunistic infection/immune
reconstitution infection syndromes after HAART
initiation
Following HAART initiation, 496 (28.6%) patients
experienced either incident pulmonary tuberculosis, or
a WHO stage IV condition (OI/IRIS). Extra-pulmonary
tuberculosis was reported in 145 patients, pulmonary
tuberculosis in 108, wasting syndrome in 63, atypical
disseminated mycobacteriosis in 25, extra-pulmonary
Cryptococcus in 18, and other WHO stage IVconditions
in 50 (some patients presented more than one clinical
manifestation). The delay from HAART initiation to the
diagnosticofOI/IRISwasinmedian4week(IQR,2–12
weeks).
Using a multivariate Cox model, WHO stage IV (AIDS)
at HAART initiation [hazard ratio (HR), 1.35; 95% CI,
1.11–1.64, when compared with WHO stage III as the
reference category], CD4 level  100cells/ml (HR, 3.20;
95% CI, 2.05–5.00), and BMI  17kg/m
2 (HR, 1.73;
95% CI, 1.42–2.11, when compared with BMI >18.5 as
the reference category) were all independently associated
with an increased rate of OI/IRIS following HAART
initiation. Similar results were obtained when obser-
vations were censored 1 year after HAART initiation.
Discussion
In this MSF programme, 1735 patients initiated HAART
with a median CD4 cell count of only 20cells/ml. The
very severe immuno-suppression at HAART initiation
found in thisstudy is not unusual in developing countries,
where many patients discover their infection while
hospitalized for their ﬁrst opportunistic infection [12,13].
Indeed, of over 8000 patients treated worldwide by MSF,
40.4% had CD4 cell count <50cells/ml at HAART
initiation [14]. Having detailed information about
treatment response and prognosis for patients with very
low CD4 cell counts is therefore of great relevance to
physiciansworking in developing countries. The strength
of the present study is to be based in a single centre with
well established routines for patient management and data
collection, to reﬂect the outcome of a ‘real-life’treatment
programme (i.e., not a clinical trial with restrictive
inclusion criteria and intensive monitoring), to
have limited attrition (2.1% lost to follow-up), and to
be sufﬁciently large (n¼1735) for precise estimations of
CD4-stratiﬁed mortality rates.
Theﬁrstimportantﬁndingofthisstudyisthatmortalityin
the ﬁrst 2 years after HAART initiation in this resource-
poorsettingwasnotmarkedlydifferentfromthatobserved
in the industrialized world. The CD4-stratiﬁed survival
curvesdisplayedinFig.1areverysimilar tothoseshownin
the ART Cohort Collaboration initiative, a grouped
analysisofover12000adultpatientstreatedwithHAART
in the Western world [15]. The only difference was in the
severelyimmuno-compromisedgroup.PatientswithCD4
cell count  20cells/ml represented half of the study
population, and had a much worse prognosis compared
with the rest of the group. Such highly immuno-
compromised patients are no longer commonly seen in
industrialized countries, and pose a real challenge to
treating physicians in resource-poor settings. How to
initiate HAART while treating opportunistic infections,
among which tuberculosis, in these patients remains to be
further studied to minimize early mortality [14,16].
The second important ﬁnding was the similar efﬁcacy, as
judgedbythemortalityrateandthequalityoftheimmune
reconstitution, of the FDC d4T–3TC–NVP compared
with the combination d4T–3TC–EFV. These results
should be considered with caution, as assignment to
treatment regimens was not randomized, but reﬂected
changes with time of national policy recommendations.
Nevertheless,resultsremainedunchangedaftercontrolling
for potential confounders in multivariate analysis.
AlthoughpreviouscohortstudiesfavouredEFVcompared
to NVP [17–19], and the only large clinical trial gave
equivocal results [20,21], the NVP-containing FDC
represents today the most practical choice for developing
countries, considering its low cost, its ease of use (one pill
twiceaday),anditslackofteratogenicity.Inthisregard,the
results of this study, showing its comparable effectiveness
with another common regimen, are important.
Because of cost and technology limitations, viral load
measurementswerenotavailableinthisstudy.Insuchcase,
WHO recommendsthat immune reconstitution,together
withclinicalevaluation,areusedtoassesstreatmentefﬁcacy
[3]. In this study, the median CD4 cell count gain at
6m o n t h sw a sþ94cells/ml (IQR, 59–131), and at
12 months þ149cells/ml( I Q R ,9 9 –207). Similar CD4
cell count gains were observed in developing countries
[4,7,22], and slightly higher gains in industrialized
countries [10,11,23]. Some factors were found associated
with lower CD4 cellcountgains inthis study, suchasmale
gender [24] and previous ART exposure [24,25].
One should be cautious, however, on the magnitude of
theseassociations in theabsenceof control for viral load in
this study. It is recommended that chemoprophylaxis is
usedtopreventOIsatHAARTinitiationifCD4cellcount
is still low, but the CD4 cell count threshold at which
chemoprophylaxis can be stopped has not been assessed in
developingcountries.Inthisstudy,basedonmortalitydata,
cotrimoxazole prophylaxis was protective for CD4 cell
counts  200cells/ml, and ﬂuconazole prophylaxis was
protective for CD4 cell counts  100cells/ml. Moreover,
chemoprophylaxiswasfoundtostronglyreducetheriskof
death in a multivariate Cox model. The time to reach
the 200CD4cells/ml threshold was estimated in this study
at 18 and 6 months in patients initiating HAART with
baseline CD4 cell count  20 and 101–150cells/ml,
respectively.
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Identiﬁcationofasurrogatemarkerofimmuneresponseto
HAARTwouldbeofgreathelpasCD4cellcountmaynot
be available in many places for monitoring patients’
response to treatment. Total lymphocyte count, haemo-
globin, weight and BMI were considered as potential
surrogate markers, as these are easy to obtain. Although
improvements in these markers were signiﬁcantly corre-
latedwiththeCD4cellgains,withbestcorrelationsfortotal
lymphocyte count changes, the relationships were weak
(correlation coefﬁcients <0.5). Contrary to other publi-
cations [26,27], the sensitivity and speciﬁcity of various
cut-offs of total lymphocyte count changes in predicting
poor CD4 immune response never reached satisfactory
levels(both >70%) to be of use in clinical practice. Efforts
should be continued to simplify CD4 cell count testing in
the developing world, in the absence of proper surrogate
marker, to monitor patients under treatment [28].
Following HAART initiation, 496 (28.6%) of the 1735
patients enrolled in this study were diagnosed with an
incident pulmonary tuberculosis or a WHO stage IV
condition. Although we could not differentiate OIs from
IRIS, the delay from HAART initiation to diagnosis
(4 weeks in median) and the nature of these OIs (half were
extra-pulmonaryandpulmonarytuberculoses)suggestthat
the majority of these patients suffered from IRIS [29,30].
The higher incidence of IRIS in this study, compared to
industrialized countries [31,32], could be related to the
severeimmuno-suppressionofthepatients(shownasarisk
factor of IRIS in this study), and the higher prevalence of
past mycobacterial infections in the study population.
Management of IRIS is difﬁcult in resource-poor settings,
where the use of steroids is hampered by the absence of
in-depth microbiological investigations to rule out active
OIs. The elevated early mortality seen in this study and
elsewhere [5] could be partly related to IRIS, and further
studies are required to help sorting out IRIS from OIs for
better management of these patients.
In conclusion, HAART proved to be effective in patients
with CD4 cell count >20cells/ml. Further research is
requiredtoknowhowbesttoinitiateandmonitorHAART
in patients with very low CD4 cell count ( 20cells/ml),
concomitant OIs and high risk of IRIS. Meanwhile,
widespread voluntary HIV testing and counselling should
be encouraged to allow HAART initiation before the
developmentofsevereimmuno-suppression.Freeaccessto
HAART, as in this programme, is also important as
programmes in which patients had to pay for their
treatment have shown higher rates of mortality [5,33].
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